Research programme: adenosine receptor antagonists - Corvus/Vernalis

Drug Profile

Research programme: adenosine receptor antagonists - Corvus/Vernalis

Alternative Names: Adenosine A2B receptor antagonist - Corvus/Vernalis; Immune checkpoint inhibitor B - Corvus/Vernalis; VER 4066; VER 4187; VER 6623; VER 6947; VER 7835

Latest Information Update: 15 Jan 2016

Price : $50

At a glance

  • Originator Vernalis
  • Developer Corvus Pharmaceuticals; Vernalis
  • Class Purines; Pyrimidines; Thiophenes
  • Mechanism of Action Adenosine A2 receptor antagonists; Adenosine A2B receptor antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer
  • Discontinued Anxiety disorders; Major depressive disorder

Most Recent Events

  • 04 Jan 2016 Early research in Cancer in USA (unspecified route)
  • 12 Apr 2011 Biogen Idec terminates its licence for Adenosine A2A receptor antagonists
  • 21 Sep 2005 A preclinical study has been added to the Parkinson's disease pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top